TrialFuture cardiology2015

ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks.

Eli M Roth et al.PubMed ↗Publisher ↗

No numbers read from the abstract.